Effects of CYP2D6 Genotypes on Plasma Concentrations of Risperidone and Enantiomers of 9‐Hydroxyrisperidone in Japanese Patients with Schizophrenia

N. Yasui-Furukori,K. Mihara,T. Kondo,T. Kubota,T. Iga,Y. Takarada,R. Vries,S. Kaneko,T. Tateishi
DOI: https://doi.org/10.1177/0091270002239819
2003-02-01
Abstract:It has been shown that risperidone (+)‐9‐hydroxylation is enantioselectively catalyzed by the polymorphic CYP2D6 in human liver. This study aimed to examine the effect of CYP2D6 genotype on (+)‐9‐hydroxylation of risperidone in schizophrenic patients. Subjects were 38 Japanese schizophrenic inpatients receiving 6 mg/day of risperidone. Plasma concentrations of risperidone and (+)‐ and (−)‐9‐hydroxyrisperidone at steady state were quantified using LC/MS/MS and HPLC with α1 acid‐AGP chiral column, respectively. The CYP2D6*5(*5) and *10 alleles were identified using polymerase chain reaction (PCR) methods. Twenty patients had no mutated allele, 14 had one mutated allele, and 4 had two mutated alleles. There were significant differences in the steady‐state plasma concentrations of risperidone (ANOVA; p < 0.0001) among the three genotype groups, while the CYP2D6 genotype did not affect the steady‐state plasma concentrations of (+)‐9‐hydroxyrisperidone (p = 0.314) or (−)‐9‐hydroxyrisperidone (p = 0.957). The concentration ratio of risperidone to 9‐hydroxyrisperidone was strongly dependent on the CYP2D6 genotypes. This study suggests that CYP2D6 activity strongly influences the steady‐state plasma concentrations of risperidone and risperidone/9‐hydroxyrisperidone concentration ratios but is unlikely to determine enantioselectivity in the steady‐state plasma concentrations of 9‐hydroxyrisperidone in the clinical situation.
What problem does this paper attempt to address?